抗CXCR3自身抗体预测心血管风险
在无自身免疫病的4195名社区人群中,抗CXCR3自身抗体与亚临床心血管靶器官损害相关,并预测全因死亡和心源性死亡;ApoE-/-小鼠实验验证其加速动脉粥样硬化。
要点
- 抗CXCR3自身抗体高于75百分位者全因死亡风险增加25%。
- 该抗体与心源性死亡风险增加2.51倍独立相关。
- 抗体水平与内膜中层厚度、左室质量和NT-proBNP正相关。
核心结论
- 在无自身免疫病人群中,抗CXCR3自身抗体与心血管靶器官损害及全因和心源性死亡风险增加相关,并加速实验性动脉粥样硬化。
研究设计与样本
- 基于人群的古腾堡健康研究,纳入4195名无自身免疫病等排除标准的参与者,进行横断面和前瞻性分析。
- 在ApoE-/-小鼠中进行CXCR3免疫和被动抗体转移实验以验证临床发现。
主要发现
- 抗体浓度与内膜中层厚度、左室质量和NT-proBNP正相关,独立于年龄、性别、肾功能和传统危险因素。
- 蛋白组学显示抗体相关的分子特征反映免疫细胞激活和细胞因子-细胞因子受体相互作用,与Th1反应相关。
- ApoE-/-小鼠免疫CXCR3后抗体水平升高,动脉粥样硬化负荷增加,与被动转移模型中抗体浓度相关。
临床怎么用
- 抗CXCR3自身抗体可能作为心血管风险分层的新型生物标志物,尤其用于识别心源性死亡和心衰高风险个体。
- 对于无自身免疫病的人群,检测该抗体有助于评估亚临床心血管损害和炎症相关风险,但需进一步验证。
局限性
- 研究为观察性设计,不能确立因果关系;自身抗体与心血管事件的机制需更多研究。
- 排除自身免疫病、免疫调节药物、急性感染和癌症病史者,结果可能不适用于这些人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic inflammation and autoimmunity contribute to cardiovascular (CV) disease. Recently, autoantibodies (aAbs) against the CXC-motif-chemokine receptor 3 (CXCR3), a G protein-coupled receptor with a key role in atherosclerosis, have been identified. The role of anti-CXCR3 aAbs for CV risk and disease is unclear. METHODS: Anti-CXCR3 aAbs were quantified by a commercially available enzyme-linked immunosorbent assay in 5000 participants (availability: 97.1%) of the population-based Gutenberg Health Study with extensive clinical phenotyping. Regression analyses were carried out to identify determinants of anti-CXCR3 aAbs and relevance for clinical outcome (i.e. all-cause mortality, cardiac death, heart failure, and major adverse cardiac events comprising incident coronary artery disease, myocardial infarction, and cardiac death). Last, immunization with CXCR3 and passive transfer of aAbs were performed in ApoE(-/-) mice for preclinical validation. RESULTS: The analysis sample included 4195 individuals (48% female, mean age 55.5 ± 11 years) after exclusion of individuals with autoimmune disease, immunomodulatory medication, acute infection, and history of cancer. Independent of age, sex, renal function, and traditional CV risk factors, increasing concentrations of anti-CXCR3 aAbs translated into higher intima-media thickness, left ventricular mass, and N-terminal pro-B-type natriuretic peptide. Adjusted for age and sex, anti-CXCR3 aAbs above the 75th percentile predicted all-cause death [hazard ratio (HR) (95% confidence interval) 1.25 (1.02, 1.52), P = .029], driven by excess cardiac mortality [HR 2.51 (1.21, 5.22), P = .014]. A trend towards a higher risk for major adverse cardiac events [HR 1.42 (1.0, 2.0), P = .05] along with increased risk of incident heart failure [HR per standard deviation increase of anti-CXCR3 aAbs: 1.26 (1.02, 1.56), P = .03] may contribute to this observation. Targeted proteomics revealed a molecular signature of anti-CXCR3 aAbs reflecting immune cell activation and cytokine-cytokine receptor interactions associated with an ongoing T helper cell 1 response. Finally, ApoE(-/-) mice immunized against CXCR3 displayed increased anti-CXCR3 aAbs and exhibited a higher burden of atherosclerosis compared to non-immunized controls, correlating with concentrations of anti-CXCR3 aAbs in the passive transfer model. CONCLUSIONS: In individuals free of autoimmune disease, anti-CXCR3 aAbs were abundant, related to CV end-organ damage, and predicted all-cause death as well as cardiac morbidity and mortality in conjunction with the acceleration of experimental atherosclerosis.
引用
- Müller FS, Aherrahrou Z, Grasshoff H, et al. Autoantibodies against the chemokine receptor 3 predict cardiovascular risk. Eur Heart J. 2023. PMID: 37941454. doi:10.1093/eurheartj/ehad666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。